Skip to main content
Top
Published in: BMC Nephrology 1/2016

Open Access 01-12-2016 | Research article

Facility-level CKD-MBD composite score and risk of adverse clinical outcomes among patients on hemodialysis

Authors: Geoffrey A. Block, Akeem A. Yusuf, Mark D. Danese, Heidi S. Wirtz, Yan Hu, Thy P. Do, Kerry Cooper, David T. Gilbertson, Brian D. Bradbury, Allan J. Collins

Published in: BMC Nephrology | Issue 1/2016

Login to get access

Abstract

Background

Patients receiving hemodialysis with values outside of target levels for parathyroid hormone (PTH: 150–600 pg/mL), calcium (Ca: 8.4–10.2 mg/dL), and phosphate (P: 3.5–5.5 mg/dL) are at elevated morbidity and mortality risk. We examined whether patients receiving care in dialysis facilities where greater proportions of patients have at least two values out of target have a higher risk of adverse clinical outcomes.

Methods

The study cohort consisted of 39,085 prevalent hemodialysis patients in 1298 DaVita dialysis facilities as of September 1, 2009, followed from January 1, 2010, until an outcome, a censoring event, or December 31, 2010. We determined the quintile of the distribution across facilities of the proportion of patients with at least two of three parameters out of, or above, target over a 4-month baseline period. The primary composite outcome was cardiovascular hospitalization or death. Secondary outcomes included death, cardiovascular hospitalization, and parathyroidectomy. Poisson regression models were used to estimate the association of facility quintile with outcomes.

Results

Facility quintile was associated with a 7 % increased risk of cardiovascular hospitalization or death (quintile 5 versus 1, RR 1.07, 95 % CI 1.01–1.13) using the out-of-target measure of exposure and a 12 % increased risk (RR 1.12, 95 % CI 1.06–1.19) using the above-target measure. No association was seen for death using either measure. Patients in facility quintiles 3–5 (versus 1) were at increased parathyroidectomy risk (RR ranged from 2.05, 95 % CI 1.10–3.82, for quintile 3 to 2.73, 95 % CI 1.50–4.98, for quintile 5).

Conclusions

Facility level analysis of a large prevalent sample of US patients on hemodialysis demonstrates that patients in facilities with the least control of PTH, Ca, and P had the greatest risk of parathyroidectomy or the combination of cardiovascular hospitalization or death.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ishani A, Liu J, Wetmore JB, Lowe KA, Do T, Bradbury BD, et al. Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol. 2015;10:90–7.CrossRefPubMed Ishani A, Liu J, Wetmore JB, Lowe KA, Do T, Bradbury BD, et al. Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol. 2015;10:90–7.CrossRefPubMed
2.
go back to reference Block GA, Kilpatrick RD, Lowe KA, Wang W, Danese MD. CKD-Mineral and Bone Disorder and Risk of Death and Cardiovascular Hospitalization in Patients on Hemodialysis. Clin J Am Soc Nephrol. 2013;8:2132–40.CrossRefPubMedPubMedCentral Block GA, Kilpatrick RD, Lowe KA, Wang W, Danese MD. CKD-Mineral and Bone Disorder and Risk of Death and Cardiovascular Hospitalization in Patients on Hemodialysis. Clin J Am Soc Nephrol. 2013;8:2132–40.CrossRefPubMedPubMedCentral
3.
go back to reference Danese MD, Halperin M, Lowe KA, Bradbury BD, Do TP, Block GA. Refining the definition of clinically important mineral and bone disorder in hemodialysis patients. Nephrol Dial Transplant. 2015;30:1336–44.CrossRefPubMedPubMedCentral Danese MD, Halperin M, Lowe KA, Bradbury BD, Do TP, Block GA. Refining the definition of clinically important mineral and bone disorder in hemodialysis patients. Nephrol Dial Transplant. 2015;30:1336–44.CrossRefPubMedPubMedCentral
4.
go back to reference Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Workgroup. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2009;76(Suppl 113):S1–130. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Workgroup. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2009;76(Suppl 113):S1–130.
5.
go back to reference Li S, Chen YW, Peng Y, Foley RN, St Peter WL. Trends in parathyroidectomy rates in US hemodialysis patients from 1992 to 2007. Am J Kidney Dis. 2011;57:602–11.CrossRefPubMed Li S, Chen YW, Peng Y, Foley RN, St Peter WL. Trends in parathyroidectomy rates in US hemodialysis patients from 1992 to 2007. Am J Kidney Dis. 2011;57:602–11.CrossRefPubMed
6.
go back to reference Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM. Identifying persons with diabetes using Medicare claims data. Am J Med Qual. 1999;14:270–7.CrossRefPubMed Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM. Identifying persons with diabetes using Medicare claims data. Am J Med Qual. 1999;14:270–7.CrossRefPubMed
7.
go back to reference Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:1423–9.CrossRefPubMedPubMedCentral Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:1423–9.CrossRefPubMedPubMedCentral
8.
go back to reference Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol. 2004;15:442–53.CrossRefPubMed Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol. 2004;15:442–53.CrossRefPubMed
9.
go back to reference Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–18.CrossRefPubMed Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–18.CrossRefPubMed
10.
go back to reference Fernandez-Martin JL, Martinez-Camblor P, Dionisi MP, Floege J, Ketteler M, London G, COSMOS group, et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transplant. 2015;30:1542–51.CrossRefPubMed Fernandez-Martin JL, Martinez-Camblor P, Dionisi MP, Floege J, Ketteler M, London G, COSMOS group, et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transplant. 2015;30:1542–51.CrossRefPubMed
11.
go back to reference Shroff R, Long DA, Shanahan C. Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol. 2013;24:179–89.CrossRefPubMed Shroff R, Long DA, Shanahan C. Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol. 2013;24:179–89.CrossRefPubMed
12.
go back to reference Shanahan CM. Mechanisms of vascular calcification in CKD-evidence for premature ageing? Nat Rev Nephrol. 2013;9:661–70.CrossRefPubMed Shanahan CM. Mechanisms of vascular calcification in CKD-evidence for premature ageing? Nat Rev Nephrol. 2013;9:661–70.CrossRefPubMed
13.
go back to reference Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367:2482–94.CrossRefPubMed Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367:2482–94.CrossRefPubMed
14.
go back to reference Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349:446–56.CrossRefPubMed Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349:446–56.CrossRefPubMed
15.
go back to reference Li J, Molnar MZ, Zaritsky JJ, Sim JJ, Streja E, Kovesdy CP, et al. Correlates of parathyroid hormone concentration in hemodialysis patients. Nephrol Dial Transplant. 2013;28:1516–25.CrossRefPubMedPubMedCentral Li J, Molnar MZ, Zaritsky JJ, Sim JJ, Streja E, Kovesdy CP, et al. Correlates of parathyroid hormone concentration in hemodialysis patients. Nephrol Dial Transplant. 2013;28:1516–25.CrossRefPubMedPubMedCentral
16.
go back to reference Brunelli SM, Sibbel S, Do TP, Cooper K, Bradbury BD. Facility dialysate calcium practices and clinical outcomes among patients receiving hemodialysis: a retrospective observational study. Am J Kidney Dis. 2015;66:655–65.CrossRefPubMed Brunelli SM, Sibbel S, Do TP, Cooper K, Bradbury BD. Facility dialysate calcium practices and clinical outcomes among patients receiving hemodialysis: a retrospective observational study. Am J Kidney Dis. 2015;66:655–65.CrossRefPubMed
Metadata
Title
Facility-level CKD-MBD composite score and risk of adverse clinical outcomes among patients on hemodialysis
Authors
Geoffrey A. Block
Akeem A. Yusuf
Mark D. Danese
Heidi S. Wirtz
Yan Hu
Thy P. Do
Kerry Cooper
David T. Gilbertson
Brian D. Bradbury
Allan J. Collins
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2016
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-016-0382-8

Other articles of this Issue 1/2016

BMC Nephrology 1/2016 Go to the issue